Plexin-D1 antibody detection kit and application thereof in nervous system pain diseases

By preparing and applying the Plexin-D1 antibody detection kit, the problem of differentiating autoimmune diseases of the nervous system has been solved, achieving highly sensitive diagnosis of symptoms such as neuropathic pain and trigeminal neuralgia, and promoting the development of treatment methods targeting Plexin-D1.

CN118962156AInactive Publication Date: 2024-11-15AVICENA (GUANGZHOU) HEALTH TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411303971.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current technologies struggle to effectively differentiate between autoimmune and non-autoimmune diseases of the nervous system, particularly in symptoms such as neuropathic pain and trigeminal neuralgia, where sensitive diagnostic methods are lacking.

Method used

A Plexin-D1 antibody detection kit was developed, comprising Plexin-D1 antibody, immunofluorescence solution A, and immunofluorescence solution B. The Plexin-D1 antigen protein particles were prepared and Plexin-D1 antibody was expressed in 293T cells. The kit was then used to detect the expression and distribution of Plexin-D1 antibody by combining immunofluorescence technology.

Benefits of technology

It provides highly sensitive diagnostic tools that can differentiate between autoimmune and non-autoimmune diseases, helping to understand disease mechanisms and offering new options for the treatment of neurological pain disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118962156A_ABST
    Figure CN118962156A_ABST
Patent Text Reader

Abstract

The invention discloses the technical field of gene detection, and particularly relates to a Plexin-D1 antibody detection kit and application of the Plexin-D1 antibody detection kit in nervous system pain diseases, and the kit comprises a Plexin-D1 antibody reagent, an immunofluorescence A solution and an immunofluorescence B solution. The potential effect of the Plexin-D1 in nervous system diseases can be determined by comparing Plexin-D1 expression in normal and disease states, and the Plexin-D1 has high sensitivity and can distinguish autoimmune diseases from non-autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of gene detection, and specifically refers to a Plexin-D1 antibody detection kit and its application in neurological pain diseases. Background Art

[0002] Autoimmune diseases of the nervous system are diseases caused by immune molecules or cells attacking the nervous system, with a wide range of clinical manifestations, including sensory motor abnormalities, cognitive consciousness disorders, behavioral or mental abnormalities, neuropathic pain (NeP), etc. Among them, neuropathic pain is closely related to the interaction between autoantibodies. IgG-mediated pain disorders caused by specific autoantibodies to antigens in the somatosensory pathway are one of the main causes of neuropathic pain in autoimmune diseases of the nervous system; indirect immunofluorescence tests of mouse tissues were used to screen serum autoantibodies that specifically bind to pain-conducting dorsal root ganglia (DRG) and spinal cord dorsal horns in the somatosensory pathway. As a result, specific IgG against DRG neurons and their nerve endings were found in samples with NeP. Double immunostaining of IgG and DRG neuron markers of diseased mice and western blotting were performed. After analyzing the immunoprecipitates, Plexin-D1 was determined to be the autoantigen that causes DRG. The clinical manifestations are neuralgia or other unexplained neuropathic pain caused by immune inflammation (including nervous system immune diseases) and allergic diseases; trigeminal neuralgia.

[0003] Plexin-D1 is a transmembrane protein belonging to the Plexin family. This family is mainly involved in intercellular signaling. Plexin-D1 plays an important role in multiple physiological processes such as neural development, immune response, and cardiovascular system development. Plexin-D1 is a receptor for Semaphorin molecules, especially for Class 3 When semaphorins (such as Sema3E) bind, they participate in regulating cell migration, cell morphology and dynamic changes of the cytoskeleton by regulating the activity of Rho family GTPases. Plexin-D1 is a cell surface receptor for class 3 and class 4 semaphorins, expressed in the nervous system, thymocytes, activated B cells, macrophages, dendritic cells and endothelial cells. Since Plexin-D1 exists on the cell surface as a transmembrane protein, anti-cell surface autoantibodies can directly contact nerve cell surface molecules and cause pathological reactions through the following mechanisms: First, antibodies can affect the distribution of receptors on the cell membrane surface or cause them to be internalized, thereby causing abnormal neuronal function; second, antibodies can destroy the interaction between antigen proteins and block the model pathway, thereby causing abnormalities; third, antibodies can stimulate receptors to antagonize; fourth, antibodies can form complexes with antigens to produce cytotoxicity; fifth, antibodies can enter cells through endocytosis of the cell membrane and cause pathological reactions. Summary of the invention

[0004] In view of the above situation, in order to overcome the defects of the prior art, the technical solution adopted by the present invention is as follows: The present invention provides a Plexin-D1 antibody detection kit, which includes a Plexin-D1 antibody reagent, an immunofluorescence A solution, and an immunofluorescence B solution; Preferably, the immunofluorescence solution A is used for sample dilution, and its components include PBST and guinea pig liver powder; Preferably, the immunofluorescence solution B includes FITC-labeled anti-human IgG antibody and is diluted with 1% BSA.

[0005] The present invention provides a method for preparing a Plexin-D1 antibody detection kit, which specifically comprises the following steps: S1. According to the gene sequence of the Plexin-D1 antigen protein shown in SEQ ID NO: 1, pcDNA3.1 is used as a vector template, the pcDNA3.1 vector is double-digested with restriction endonucleases, PCR amplified and the product is purified, and the Plexin-D1 gene fragment cut with the pcDNA3.1 vector is connected with T4 DNA ligase to obtain a plasmid containing the Plexin-D1 gene sequence; Preferably, in step S1, the primer sequences used to construct the plasmid containing the Plexin-D1 gene sequence include: Upstream primer: 5′-AAGCTTATGCACTCGCCGCGCCGCGC-3′; Downstream primer: 5′-GAATTCAGGTTTGTCCGTAAGGC-3′; S2. Add the plasmid containing the Plexin-D1 gene sequence described in step S1 into the competent cells of Escherichia coli C41 (DE3), perform electroporation, add 500 µL LB medium, and resuscitate in a shaker at 37°C for 1 hour. Spread the resuscitated cells on LB agar plates containing ampicillin (50-100 µg / mL), and incubate at 37°C overnight. S3. Use lipofectamine2000 to transfect the constructed pcDNA3.1-Plexin-D1 recombinant plasmid into 293T cells cultured in vitro, and culture under specific conditions for 48 hours to induce cell replication and protein expression; Preferably, in step S3, the 293T cell form protein sequence is as shown in SEQ ID NO: 2; S4, washing-fixing-washing-drying-perforation-blocking-wet storage of the 293T cells cultured in step S3 to obtain Plexin-D1 antibody reagent; S5. The Plexin-D1 antibody reagent prepared in step S4, immunofluorescence solution A and immunofluorescence solution B are combined to obtain a Plexin-D1 antibody detection kit.

[0006] The present invention also provides an application of a Plexin-D1 antibody detection kit in nervous system pain diseases, wherein the symptoms of the nervous system autoimmune neuralgia diseases include at least one of neuropathic pain and trigeminal neuralgia; Preferably, the Plexin-D1 antibody detection kit is used to distinguish autoimmune diseases, and further, to distinguish autoimmune diseases of the nervous system from non-autoimmune diseases.

[0007] The beneficial effects achieved by the present invention are as follows: The present invention provides a Plexin-D1 antibody detection kit and its application in nervous system pain diseases. Plexin-D1 is a cell membrane protein that participates in the regulation of nerve development and signal transduction in the nervous system. The role of Plexin-D1 in various nervous system pain diseases has gradually attracted attention. By comparing the expression of Plexin-D1 in normal and disease states, its potential role in nervous system diseases can be determined. It has high sensitivity and can distinguish autoimmune diseases from non-autoimmune diseases. Exploring the specific role of Plexin-D1 in pain diseases is helpful to understand the disease mechanism, promote the development of drugs or treatment methods for Plexin-D1, and provide new treatment options for pain diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Figure 1 The 293T cells carrying the recombinant gene vector of Plexin-D1 antigen protein have a clearly identifiable green fluorescence result image; Figure 2 This is a graph showing the test results of Example 2 on mouse cerebrospinal fluid.

[0009] The accompanying drawings are used to provide further understanding of the present invention and constitute a part of the specification. They are used to explain the present invention together with the embodiments of the present invention and do not constitute a limitation of the present invention. DETAILED DESCRIPTION

[0010] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments; based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0011] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein may be applied to the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only and are not intended to limit the content of this application.

[0012] The experimental methods in the following examples are conventional methods unless otherwise specified; the experimental materials and test strains used in the following examples are purchased from commercial channels unless otherwise specified.

[0013] Example 1 This embodiment provides a method for preparing a Plexin-D1 antibody detection kit, which specifically comprises the following steps: S1. According to the gene sequence of the Plexin-D1 antigen protein as shown in SEN ID NO: 1, the designed primer sequences are as follows: upstream primer: 5'-AAGCTTATGCACTCGCCGCGCCGCGC-3'; downstream primer: 5'-GAATTCAGGTTTGTCCGTAAGGC-3'; the pcDNA3.1 vector is double-digested with restriction endonucleases, and PCR amplification is performed according to the primer sequences to insert the gene sequence of Plexin-D1 into the pcDNA3.1 vector template; high-fidelity enzyme 2X premix solution is used, and the amplification temperature program includes the following according to the length of the amplified fragment: initial denaturation: 95°C, 3 minutes; cycle stage (repeated 28 times): denaturation: 95°C, 30S; annealing: 49°C, 45s; extension: 72°C, 1.2min; final extension: 72°C, 5-10 minutes; storage: 4°C; S2. Inoculate Escherichia coli C41 (DE3) into 5 mL of LB medium containing fresh mold, and culture at 37°C with shaking overnight. Take 1 mL of the overnight cultured bacterial solution and add it to 100 mL of LB medium. Culture with shaking at 150 rpm and 37°C. Detect the OD600 of the bacterial solution. Stop the culture when the OD600 is 0.54. Cool the culture in an ice water bath for 15 min, transfer it to a precooled centrifuge tube, centrifuge it at 4°C, 4000 g for 15 min, collect the precipitate, resuspend it with sterile water, centrifuge it at 4°C, 4000 g for 15 min, collect the precipitate, resuspend it with sterile 10% glycerol solution, centrifuge it at 4°C, 4000 g for 15 min, collect the precipitate, add the treatment prepared in step S1, incubate it on ice for 10 min, transfer it to a precooled electric shock cup on ice, and start the electric shock program. Voltage: 2.0 kV, resistance: 200Ω and capacitance: 25μF; after the electric shock, immediately add 1ml of fresh LB medium, transfer to a sterile EP tube under sterile conditions, culture at 37°C with shaking for about 50min, centrifuge at 4000g for 15min at 4°C, spread on an LB plate containing 50-100µg / mL ampicillin, and incubate at 37°C overnight; S3. One day before transfection, 293T cells were seeded in a 6-well plate culture dish with 10% FBS DMEM culture medium. The cell density should reach 63.2%. Lipofectamine transfection reagent and Opti-MEM were diluted to 20-50 µL according to 5 µL per well. The diluted DNA and diluted transfection reagent were mixed at room temperature and allowed to stand for 15 minutes to form a DNA-liposome complex. The culture medium in the 293T cell culture dish was removed, 1 mL of fresh Opti-MEM was added, and the DNA-liposome complex was evenly added to the cell culture medium. The culture dish was gently shaken to mix evenly. After culturing the cells in a 37°C, 5% CO2 incubator for 5 hours, the culture medium was replaced with a regular culture medium containing 10% FBS (without antibiotics), and the culture was continued for 48 hours. The expression of the Plexin-D1 gene was detected. The 293T cell form protein sequence is shown in SEQ ID NO:2. S4. Remove the cell culture medium, wash the cells gently 3 times with calcium- and magnesium-free PBS buffer to remove residual culture medium and cell metabolites, add 4% PFA, incubate at room temperature for 15 minutes to fix the cells, discard PFA after fixation, wash the cells again with PBS buffer 2-3 times to remove excess fixative to prevent interference with subsequent steps, after washing the cells, air-dry the cells on the slide for 5 minutes, treat the cells with 0.1% Triton X-100 solution at room temperature for 10 minutes, perform perforation treatment, incubate with 5% bovine serum albumin (BSA) at room temperature for 45 minutes, use PBS containing 0.02% sodium azide for wet storage, store in a 4°C refrigerator, and obtain Plexin-D1 antibody reagent for standby use; S5, combining the Plexin-D1 antibody reagent prepared in step S4, immunofluorescence solution A and immunofluorescence solution B to obtain a Plexin-D1 antibody detection kit; Goat-derived Plexin-D1 antigen protein antibody was purchased as the primary antibody, and 488-labeled monkey anti-goat IgG antibody was used as the secondary antibody; the operation steps were: incubation of primary antibody - washing - incubation of secondary antibody - washing - imaging - taking pictures - dual-channel synthesis; forming a contrast image with unstained cells as negative control and green fluorescent stained cells as positive results, with negative as image A and positive as image B. Figure 1 The results showed that 293T cells transfected with the recombinant gene vector of Plexin-D1 antigen protein had obvious identifiable green fluorescence results.

[0014] Example 2 This embodiment provides an application of a Plexin-D1 antibody detection kit in nervous system pain diseases: Anesthetized female ICR mice (10-12 weeks old) were injected intrathecally with 20 μL of purified IgG. A control group without IgG injection was set up. The intervertebral space between the fifth and sixth lumbar vertebrae was entered by percutaneous puncture. The tail flick induced by injection ensured the injection accuracy. 24 hours after the injection, the mice were observed to develop neuropathic pain symptoms. The cerebrospinal fluid of the mice was measured using the above kit, and the fluorescence images were as shown in Figure 2. Figure 2 As shown, in the treatment group (image B), there is obvious green fluorescence, while in the control group (image A), the green fluorescence is not obvious.

[0015] Experimental example In this experimental example, the affinity of the antibody reagent prepared in Example 1 was analyzed using an AMC sensor. The reference substance was an antibody synthesized according to the plexin-D1 protein sequence downloaded from the NBCI website. The operation process of the AMC sensor was as follows: the purified Plexin-D1 antibody was placed in a PBST buffer for equilibration for 60 seconds, the antibody was solidified in the antibody solution for 5 minutes, and then transferred to a newly configured PBST buffer for incubation for 3 minutes, placed in an antigen solution for binding for 8 minutes, and then transferred to a PBST buffer for dissociation. The sensor was regenerated using a 10mM GLY solution / PBST buffer. The data are shown in the following table; this shows that the affinity of the antibody reagent described in Example 1 is equivalent to that of the control sample.

[0016] Where KD represents the equilibrium dissociation constant or affinity; kon represents the binding rate.

[0017] While the embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that many changes, modifications, substitutions and variations can be made to the embodiments without departing from the principles and spirit of the invention.

[0018] The present invention and its implementation methods are described above, which is not restrictive. The drawings are only one of the implementation methods of the present invention, and the actual application is not limited thereto. In short, if ordinary technicians in the field are inspired by it and design methods and embodiments similar to the technical solution without creativity without departing from the purpose of the invention, they should all fall within the protection scope of the present invention.

Claims

1. A Plexin-D1 antibody detection kit, characterized in that: The kit includes Plexin-D1 antibody reagent, immunofluorescence solution A and immunofluorescence solution B; The immunofluorescence solution A is used for sample dilution, and its components include PBST and guinea pig liver powder; The immunofluorescence B solution includes IgG antibodies and is diluted with 1% BSA.

2. The method for preparing a Plexin-D1 antibody detection kit according to claim 1, characterized in that: The specific steps include: S1. According to the gene sequence of the Plexin-D1 antigen protein shown in SEQ ID NO: 1, pcDNA3.1 is used as a vector template, the pcDNA3.1 vector is double-digested with restriction endonucleases, PCR amplified and the product is purified, and the Plexin-D1 gene fragment cut with the pcDNA3.1 vector is connected with T4 DNA ligase to obtain a plasmid containing the Plexin-D1 gene sequence; S2, adding the plasmid containing the Plexin-D1 gene sequence described in step S1 into the competent E. coli cells, performing electroporation, adding 500 µL LB medium, resuscitating in a shaker at 37°C for 1 hour, spreading the resuscitated cells on an LB agar plate containing ampicillin, and incubating at 37°C overnight; S3, using liposome transfection reagent to transfect the constructed pcDNA3.1-Plexin-D1 recombinant plasmid into 293T cells cultured in vitro, and culturing under specific conditions for 48 hours to induce cell replication and protein expression; S4, washing-fixing-washing-drying-perforation-blocking-wet storage of the 293T cells cultured in step S3 to obtain Plexin-D1 antibody reagent; S5. The Plexin-D1 antibody reagent prepared in step S4, immunofluorescence solution A and immunofluorescence solution B are combined to obtain a Plexin-D1 antibody detection kit.

3. The method for preparing a Plexin-D1 antibody detection kit according to claim 2, characterized in that: In step S1, the primer sequences used to construct a plasmid containing the Plexin-D1 gene sequence include: Upstream primer: 5′-AAGCTTATGCACTCGCCGCGCCGCGC-3′; Downstream primer: 5′-GAATTCAGGTTTGTCCGTAAGGC-3′.

4. The method for preparing a Plexin-D1 antibody detection kit according to claim 3, characterized in that: In step S3, the 293T cell form protein sequence is shown as SEQ ID NO:

2.

5. Use of the Plexin-D1 antibody detection kit according to claim 1 in treating pain diseases of the nervous system, characterized in that: The symptoms of the autoimmune neuralgia of the nervous system include at least one of neuropathic pain and trigeminal neuralgia.

6. Use of the Plexin-D1 antibody detection kit according to claim 5 in treating pain diseases of the nervous system, characterized in that: The Plexin-D1 antibody detection kit is used to differentiate autoimmune diseases.

7. Use of the Plexin-D1 antibody detection kit according to claim 6 in treating pain diseases of the nervous system, characterized in that: Used to differentiate autoimmune from non-autoimmune diseases of the nervous system.

Citation Information

Patent Citations

  • biomarker

    US20150125514A1

  • Neuropathic pain marker and use thereof

    WO2018190365A1